Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 25,184 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: The Bronx, New York • Houston, Texas • Charlottesville, Virginia

Conditions: Osteopathic Manipulative Treatment (OMT) Effects on Cerebrospinal Fluid (CSF) Dynamics
Interventions: Osteopathic Manipulative Treatment (OMT); Other
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Alcohol Consumption
Interventions: Drinking Cognition Feedback (DCF), Alcohol Risk Feedback (ARF), Adaptive Goal Support (AGS), COMBO; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 25 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Pain
Interventions: Group cognitive behavioral therapy, Pain education; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: HIV
Interventions: FP conjugate vaccine (25 mcg), FP conjugate vaccine (200 mcg), Trimer 6931 (100 mcg), Trimer 6931 (200 mcg), Trimer 4571 (200 mcg), Trimer 4571 (100 mcg); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: brimonidine 0.1%, Apraclonidine 0.5%; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions: Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cerebrovascular Stroke
Interventions: Transcranial Magnetic Stimulation, Traditional Paired Associative Stimulation, Median Nerve Stimulation, Corticocortical Paired Associative Stimulation, Sham Paired Associative Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hiv, Opioid Use Disorder
Interventions: community-friendly health recovery program, Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis; Behavioral · Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: Non-contrast Computed Tomography (CT) Scans (Metallic Markers), Non-contrast CT Scans (Metallic Markers); Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Associated Polyneuropathy
Interventions: Transcutaneous Auricular Vagus Nerve Stimulation (AVNS); Device
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: JNJ-42756493; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia
Interventions: Sargramostim (GM-CSF), Pneumococcal Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma
Interventions: Medical Device Usage and Evaluation, Questionnaire Administration; Device · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Kidney Transplantation
Interventions: Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more

Conditions: Incisional Hernia of Anterior Abdominal Wall
Interventions: Long-acting absorbable mesh; Device
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: AIDS-Related-Primary Central Nervous System Lymphoma
Interventions: Methotrexate, Rituximab, Leucovorin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, OA, Knee Osteoarthritis
Interventions: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP); Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 30
States / cities: Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 26 more

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Smoking Cessation, Weight, Body
Interventions: Liraglutide, Placebo, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: Rebecca Ashare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Weight Loss, Gastrectomy
Interventions: Gastric Point of Care Ultrasound; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Dyskeratosis Congenita, Aplastic Anemia
Interventions: Campath 1H, Cyclophosphamide, Fludarabine, Total Body Irradiation, Stem Cell Transplantation, antithymocyte globulin, Methylprednisolone; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd Trimester
Interventions: GE VScan Access R2 Ultrasound System, GE Corometrics 170 Series Fetal Monitor; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Search by objective public record fields.

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Exploring How Osteopathic Manipulative Treatment May Affect Spinal Fluid Flow: An MRI Study

Mechanisms for Alcohol Treatment Change [MATCH] Study

Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

Tandem Auto-Allo Transplant for Lymphoma

Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke

Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx

Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral Neuropathy

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

Phasix Mesh Underlay During Loop Ileostomy Closure

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Daily Liraglutide for Nicotine Dependence

Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Vscan Access R2 Feasibility Evaluation